General
Preferred name
FUROSEMIDE
Synonyms
Frusemide Sodium ()
Lasix ()
Furosemide (sodium) ()
NSC 269420 ()
Lasix, Frusemide Sodium ()
Furosemide (NSC 269420) ()
Furosemide sodium ()
Aluzine 40 ()
Lasix Ret ()
Diuresal ()
Tenkofruse ()
Aluzine 20 ()
Hydroled ()
Frusid ()
LB-502 ()
Aquamed ()
Furosemida ()
Logirene ()
Frusetic ()
NSC-269420 ()
Aluzine 500 ()
Marsemide ()
Froop ()
Frusemide ()
Oedemex ()
Frumil ()
Rusyde ()
Frusol ()
Mirfat ()
Frumax ()
Furosemidum ()
Furoscix ()
Dryptal ()
Furosemide-d5 ()
P&D ID
PD002324
CAS
54-31-9
41733-55-5
106391-48-4
1189482-35-6
Tags
available
drug
Approved by
FDA
First approval
1966
Drug indication
Congestive heart failure
Drug Status
vet_approved
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Furosemide is a loop diuretic drug. (GtoPdb)
DESCRIPTION Furosemide is a potent and orally active inhibitor of Na+/K+/2Cl- (NKCC) cotransporter, NKCC1 and NKCC2[1]. Furosemide is also a GABAA receptors antagonist and displays 100-fold selectivity for ¦Á6-containing receptors than ¦Á1-containing receptors. Furosemide acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema[2].
PRICE 29
DESCRIPTION Furosemide sodium is a potent and orally active inhibitor of Na+/K+/2Cl-?(NKCC) cotransporter, NKCC1 and NKCC2[1].?Furosemide sodium is also a GABAA?receptors antagonist and displays 100-fold selectivity for?¦Á6-containing receptors than?¦Á1-containing receptors. Furosemide sodium acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema[2].
DESCRIPTION Furosemide sodium (Frusemide Sodium) is a potent and orally active inhibitor of Na+/K+/2Cl- (NKCC) cotransporter, NKCC1 and NKCC2. Furosemide sodium is also a GABAA receptors antagonist and displays 100-fold selectivity for ??6-containing receptors than ??1-containing receptors. Furosemide sodium acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema.
DESCRIPTION Ligand of the translocator protein (TSPO); also GABAA receptor potentiator (Tocris Bioactive Compound Library)
DESCRIPTION Na+/2Cl-/K+ (NKCC) symporter inhibitor. Also antagonizes GABAA (Tocriscreen Plus)
DESCRIPTION Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure. It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body. (Enamine Bioactive Compounds)
DESCRIPTION Furosemide sodium (Frusemide Sodium) is a potent and orally active inhibitor of Na+/K+/2Cl- (NKCC) cotransporter, NKCC1 and NKCC2. Furosemide sodium is also a GABAA receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide sodium acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
2
Compound Sets
33
AdooQ Bioactive Compound Library
A10412
Cayman Chemical Bioactives
17273
26298
31789
ChEMBL Approved Drugs
CHEMBL35
ChEMBL Drugs
CHEMBL35
Concise Guide to Pharmacology 2017/18
4839
Concise Guide to Pharmacology 2019/20
4839
Concise Guide to Pharmacology 2021/22
4839
Concise Guide to Pharmacology 2023/24
4839
Drug Repurposing Hub
DrugBank
DB00695
DrugBank Approved Drugs
DB00695
DrugCentral
1258
DrugCentral Approved Drugs
1258
DrugMAP
DMMQ8ZG
DrugMAP Approved Drugs
DMMQ8ZG
DrugMatrix
Enamine Bioactive Compounds
EBC-06772
Enamine BioReference Compounds
Guide to Pharmacology
4839
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL35
Mcule NIBR MoA Box Subset
MCULE-8037874224
MedChem Express Bioactive Compound Library
HY-B0135
HY-B0135A
NCATS Inxight Approved Drugs
7LXU5N7ZO5
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Furosemide(Lasix)
furosemide-sodium
TargetMol Bioactive Compound Library
T35336
The Spectrum Collection
Tocris Bioactive Compound Library
3109
Tocriscreen Plus
3109
External IDs
67
Properties
(calculated by RDKit )
Molecular Weight
330.01
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
3
Rotatable Bonds
5
Ring Count
2
Aromatic Ring Count
2
cLogP
1.89
TPSA
122.63
Fraction CSP3
0.08
Chiral centers
0.0
Largest ring
6.0
QED
0.77
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Transporters
Target
GABA Receptor
NKCC1
NKCC2
CA2, GPR35, SLC12A1, SLC12A2
NKCC
GABA Receptor,NKCC
Primary Target
Na+/K+/Cl- Symporter
MOA
Inhibitor
Antidiuretic
diuretic
Member status
virtual
Indication
edema, hypertension, congestive heart failure, nephrotic syndrome
Disease Area
cardiology, rheumatology
Therapeutic Class
Diuretics
Pathway
Membrane Transporter/Ion Channel
Neuroscience
Neuronal Signaling
Source data